- Home
- BATL vs BRNS Comparison
BATL vs BRNS Comparison
Compare BATL & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BATL | BRNS |
|---|---|---|
| Founded | 1987 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8M | 30.4M |
| IPO Year | 2004 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BATL | BRNS |
|---|---|---|
| Price | $1.34 | $0.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 3.5M | 88.1K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $166,043,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.00 | $0.51 |
| 52 Week High | $29.70 | $1.83 |
Technical Indicators
Market Signals| Indicator | BATL | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 48.02 | 60.28 |
| Support Level | $1.27 | $0.65 |
| Resistance Level | $1.44 | $0.74 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 32.61 | 66.07 |
Price Performance
Historical ComparisonAbout BATL Battalion Oil Corporation
Battalion Oil Corp is an independent energy company focused on the acquisition, production, exploration, and development of onshore liquids-rich oil and natural gas assets in the U.S. Its properties and drilling activities are currently focused in the Delaware Basin.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.